HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf Goal For Nivea Includes 250 Market-Leading Positions By 2006

This article was originally published in The Rose Sheet

Executive Summary

Beiersdorf's expansion plans for Nivea call for capturing 250 market-leading positions worldwide by 2006, the German firm said in its Feb. 5 1year-end sales release

You may also be interested in...



Beiersdorf sales

Nivea generated $2.75 bil. (€1=$1.06) in 2002, fueling 7.2% gain in Beiersdorf's Cosmed division, German company announces in 1preliminary 2002 sales and earnings release Jan. 15. Cosmed division sales reached $3.35 bil., and earnings before interest and taxes increased approximately 13%, Beiersdorf says. Consolidated sales increased 4.4% to $5.02 bil., and after tax profit was $303.5 mil., an increase of approximately 23.7%. Endorsement of the financial statement by a supervisory board is scheduled for mid March, and Beiersdorf's annual press conference will be held April 2...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel